Sol-Gel Technologies Ltd. (SLGL)
NasdaqCM · USD · Healthcare · Biotechnology
$70.81 (+1.69%) as of
Key statistics
- Market cap
- 231.83M
- Forward P/E
- -8.82
- EPS (TTM)
- -5.61
- Dividend yield
- 0.00%
- 52-week range
- 28.81 – 97.97
- Beta
- 1.15
- Revenue (TTM)
- 1.79M
- Profit margin
- 0.00%
- Analyst target
- $152.50
- Volume
- 7.59k
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ness Ziona, Israel
- Employees
- 28
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.